Learn about dose escalation Getting your patients started Important Safety Information for Wegovy WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
November 2025: One of the physicians and researchers who investigated the link between Wegovy and vision loss is continuing his research on a link between the drug and condition
However, much of that early change often comes from reduced inflammation, glycogen depletion, and water lossnot 20 pounds of body fat
Rybelsus approved for T2D
Patients should maintain regular follow-up with their healthcare provider throughout tirzepatide therapy, typically every 412 weeks initially, then less frequently once stable
Acknowledgements We thank L MHamdi and L Puydenus from SBEC-BEC (Support Biopathologique aux Etudes Cliniques - Bureau des Etudes Cliniques) from Institut Claudius Regaud-IUCT-Oncopole for TMAs and technical support
